🚀 VC round data is live in beta, check it out!
Samsung BioLogics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Samsung BioLogics and similar public comparables like Lonza Group, Wuxi AppTec, IQVIA, Sartorius and more.
Samsung BioLogics Overview
About Samsung BioLogics
Samsung BioLogics Co Ltd is a biopharmaceutical company engaged in drug development and manufacturing services. The company operates two segments: Biopharmaceutical Development and Commercialization, and Contract Development and Manufacturing Organization (CDMO). The Biopharmaceutical Development and Commercialization segment focuses on developing and commercializing biosimilars across therapeutic areas, including autoimmune, oncology, ophthalmology, and hematology. The Contract Development and Manufacturing Organization (CDMO) segment provides biopharmaceutical contract manufacturing along with cell line and process development services. It generates the majority of its revenue from the CDMO segment.
Founded
2011
HQ
Employees
5.0K
Website
Financials (LTM)
EV
$50B
Samsung BioLogics Financials
Samsung BioLogics reported last 12-month revenue of $3B and EBITDA of $2B.
In the same LTM period, Samsung BioLogics generated $2B in gross profit, $2B in EBITDA, and $1B in net income.
Revenue (LTM)
Samsung BioLogics P&L
In the most recent fiscal year, Samsung BioLogics reported revenue of $3B and EBITDA of $2B.
Samsung BioLogics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $2B | XXX | $2B | XXX | XXX | XXX |
| EBITDA Margin | 55% | XXX | 61% | XXX | XXX | XXX |
| EBIT Margin | 45% | XXX | 45% | XXX | XXX | XXX |
| Net Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Net Margin | 36% | XXX | 39% | XXX | XXX | XXX |
| Net Debt | — | — | $521M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Samsung BioLogics Stock Performance
Samsung BioLogics has current market cap of $50B, and enterprise value of $50B.
Market Cap Evolution
Samsung BioLogics' stock price is $1,083.28.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $50B | $50B | -1.2% | XXX | XXX | XXX | $26.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSamsung BioLogics Valuation Multiples
Samsung BioLogics trades at 15.2x EV/Revenue multiple, and 27.8x EV/EBITDA.
EV / Revenue (LTM)
Samsung BioLogics Financial Valuation Multiples
As of April 18, 2026, Samsung BioLogics has market cap of $50B and EV of $50B.
Equity research analysts estimate Samsung BioLogics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Samsung BioLogics has a P/E ratio of 42.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $50B | XXX | $50B | XXX | XXX | XXX |
| EV (current) | $50B | XXX | $50B | XXX | XXX | XXX |
| EV/Revenue | 15.2x | XXX | 16.1x | XXX | XXX | XXX |
| EV/EBITDA | 27.8x | XXX | 26.4x | XXX | XXX | XXX |
| EV/EBIT | 33.6x | XXX | 35.4x | XXX | XXX | XXX |
| EV/Gross Profit | 27.7x | XXX | 29.2x | XXX | XXX | XXX |
| P/E | 42.9x | XXX | 41.5x | XXX | XXX | XXX |
| EV/FCF | 87.8x | XXX | 95.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Samsung BioLogics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Samsung BioLogics Margins & Growth Rates
Samsung BioLogics' revenue in the last 12 month grew by 17%.
Samsung BioLogics' revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.1M for the same period.
Samsung BioLogics' rule of 40 is 73% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Samsung BioLogics' rule of X is 102% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Samsung BioLogics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Margin | 55% | XXX | 61% | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 73% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 102% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 10% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Samsung BioLogics Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Samsung BioLogics | XXX | XXX | XXX | XXX | XXX | XXX |
| Lonza Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Wuxi AppTec | XXX | XXX | XXX | XXX | XXX | XXX |
| IQVIA | XXX | XXX | XXX | XXX | XXX | XXX |
| Sartorius | XXX | XXX | XXX | XXX | XXX | XXX |
| Wuxi Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Samsung BioLogics M&A Activity
Samsung BioLogics acquired XXX companies to date.
Last acquisition by Samsung BioLogics was on XXXXXXXX, XXXXX. Samsung BioLogics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Samsung BioLogics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSamsung BioLogics Investment Activity
Samsung BioLogics invested in XXX companies to date.
Samsung BioLogics made its latest investment on XXXXXXXX, XXXXX. Samsung BioLogics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Samsung BioLogics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Samsung BioLogics
| When was Samsung BioLogics founded? | Samsung BioLogics was founded in 2011. |
| Where is Samsung BioLogics headquartered? | Samsung BioLogics is headquartered in South Korea. |
| How many employees does Samsung BioLogics have? | As of today, Samsung BioLogics has over 5K employees. |
| Who is the CEO of Samsung BioLogics? | Samsung BioLogics' CEO is John Lim. |
| Is Samsung BioLogics publicly listed? | Yes, Samsung BioLogics is a public company listed on Korea Exchange. |
| What is the stock symbol of Samsung BioLogics? | Samsung BioLogics trades under 207940 ticker. |
| When did Samsung BioLogics go public? | Samsung BioLogics went public in 2016. |
| Who are competitors of Samsung BioLogics? | Samsung BioLogics main competitors are Lonza Group, Wuxi AppTec, IQVIA, Sartorius. |
| What is the current market cap of Samsung BioLogics? | Samsung BioLogics' current market cap is $50B. |
| What is the current revenue of Samsung BioLogics? | Samsung BioLogics' last 12 months revenue is $3B. |
| What is the current revenue growth of Samsung BioLogics? | Samsung BioLogics revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Samsung BioLogics? | Current revenue multiple of Samsung BioLogics is 15.2x. |
| Is Samsung BioLogics profitable? | Yes, Samsung BioLogics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Samsung BioLogics? | Samsung BioLogics' last 12 months EBITDA is $2B. |
| What is Samsung BioLogics' EBITDA margin? | Samsung BioLogics' last 12 months EBITDA margin is 55%. |
| What is the current EV/EBITDA multiple of Samsung BioLogics? | Current EBITDA multiple of Samsung BioLogics is 27.8x. |
| What is the current FCF of Samsung BioLogics? | Samsung BioLogics' last 12 months FCF is $567M. |
| What is Samsung BioLogics' FCF margin? | Samsung BioLogics' last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Samsung BioLogics? | Current FCF multiple of Samsung BioLogics is 87.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.